Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release

• Main Authors: Zuo-Jiong Gong, Fan Yang, Xiao-Qun Han, Lu-Wen Wang, Li-Kun Wang, Xun Li
• Format: Article
• Language: English
• Published: MDPI AG 2013-05-01
• Series: International Journal of Molecular Sciences
• Subjects: cisplatin; acute liver failure; high mobility group box-1; HMGB1 translocation; inflammation
• Online Access: http://www.mdpi.com/1422-0067/14/6/11224

Cisplatin is one of the most widely used chemical drugs for anticancer treatment. Recent studies have focused on the ability of cisplatin to retain the high mobility group box 1 (HMGB1) protein in cisplatin-DNA adducts, thereby preventing its release from the nucleus. Because HMGB1 is a powerful inflammatory mediator in many diseases, the aim of this study is to evaluate the therapeutic effect of cisplatin acute liver failure. In this study, low-dose cisplatin was administered to treat PMA-induced macrophage-like cells induced by PMA and rats with acute liver failure. We found that cell viability and liver injury were greatly improved by cisplatin treatment. The extracellular levels of HMGB1, TNF-α and IFN-γ were also significantly decreased by the administration of cisplatin. During inflammation, nuclear HMGB1 translocates from the nucleus to the cytoplasm. The administration of cisplatin reduced the cytoplasmic levels of HMGB1 and increased nuclear HMGB1 levels in vitro and in vivo. In conclusion, cisplatin can protect against acute liver failure by retaining HMGB1 in the nucleus and preventing its release into the extracellular milieu.